Trials / Completed
CompletedNCT02101281
Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye
An Open-label Study Evaluating Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops at Different Doses in Patients With Dry Eye
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Dompé Farmaceutici S.p.A · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study was to assess the efficacy and safety of different doses of rhNGF when administered as eye drops to patients with dry eye.
Detailed description
This is an open-label study evaluating safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops at different doses in patients with Dry Eye
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhNGF 20 µg/mL | 1 drop for each eye, twice daily for 28 day |
| DRUG | rhNGF 4 µg/mL | 1 drop each eye, twice daily for 28 day |
Timeline
- Start date
- 2014-01-20
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2014-04-02
- Last updated
- 2024-04-19
- Results posted
- 2019-08-07
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT02101281. Inclusion in this directory is not an endorsement.